Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy

Author(s): Cesar V. Borlongan, Loren E. Glover, P. R. Sanberg, David C. Hess

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 25 , 2012

Become EABM
Become Reviewer
Call for Editor


Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.

Keywords: Stem cells, transplantation, cerebral palsy, neurotrophic factor, blood brain barrier, mannitol, NF-kB, cell therapy, injured brain, stroke.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 18 July, 2012
Page: [3670 - 3676]
Pages: 7
DOI: 10.2174/138161212802002841

Article Metrics

PDF: 47